GILD Stock UPDATES Gilead Sciences (GILD) 110.72 10/29/2014

New Post Public Reply Private Reply Replies (0) Message Board

Oct 29, 2014 at 10:42 PM

Gilead Sciences (GILD) 110.72 $GILD

Final Glance: Biotechnology companies
AP - Wed Oct 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)

Stock Market Today: Stocks Not Spooked by Fed's October Taper
at The Street - Wed Oct 29, 3:19PM CDT
U.S. stock markets were not spooked by the Federal Reserve's decision to end its monthly bond buying, otherwise known as quantitative easing, this month
V: 214.66 (-2.05), GILD: 110.72 (-2.73), FB: 75.86 (-4.91), MET: 52.31 (+0.17), XOM: 94.59 (-0.51), DB: 31.20 (-1.28), FCAU: 10.85 (+1.13), SNY: 45.22 (-2.85)

Stock Market Today: Stocks Fall, Treasury Yields Rise as the Fed Ends Bond Buying
at The Street - Wed Oct 29, 2:09PM CDT
U.S. stocks were falling after the Federal Reserve's Open Market Committee decided to end its monthly bond buying, otherwise known as quantitative easing, this month.
V: 214.66 (-2.05), GILD: 110.72 (-2.73), FB: 75.86 (-4.91), MET: 52.31 (+0.17), XOM: 94.59 (-0.51), DB: 31.20 (-1.28), FCAU: 10.85 (+1.13), SNY: 45.22 (-2.85)

Can the Stock Market Handle the Federal Reserve Ending QE?
at The Street - Wed Oct 29, 1:15PM CDT
CNBC's "Fast Money" panel looks at life after quantitative easing program and Facebook after earnings.
HSY: 94.06 (-1.47), PNRA: 165.42 (-5.58), BWP: 17.34 (-0.11), FB: 75.86 (-4.91), C: 52.65 (+0.21), M: 57.45 (+0.18), TLT: 119.46 (+0.27), SPY: 198.11 (-0.30), QQQ: 99.81 (-0.37), GILD: 110.72 (-2.73), DIA: 169.40 (-0.26), PHM: 19.20 (-0.15), AAL: 39.94 (-0.30), TWTR: 42.08 (-1.70), X: 40.08 (+1.93)

Most active Nasdaq-traded stocks
AP - Wed Oct 29, 12:41PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
GILD: 110.72 (-2.73), FB: 75.86 (-4.91), ARCP: 10.00 (-2.38), MSFT: 46.62 (+0.13), GRPN: 5.79 (-0.21), AAPL: 107.34 (+0.60)

Midday Glance: Biotechnology companies
AP - Wed Oct 29, 12:41PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)

Stocks Worsen As Fed Announcement Looms; AmTrust Dives
at Investor's Business Daily - Wed Oct 29, 12:26PM CDT
Stocks further weakened ahead of the Fed's announcement at 2 p.m. ET. The Dow Jones industrial average and the S&P 500 joined the Nasdaq in negative territory. The Nasdaq dropped 0.6%, hurt in large part byFacebook (FB) and Gilead Sciences (GILD),...
ORB: 25.27 (-5.10), GILD: 110.72 (-2.73), FB: 75.86 (-4.91), AFSI: 46.04 (-6.99), ULTA: 121.56 (+0.59)

Stock Market Today: S&P 500 Turns Higher on Lower-Than-Forecast Oil Inventories
at The Street - Wed Oct 29, 10:01AM CDT
The S&P 500 turns higher after the Energy Information Administration said U.S. oil inventories rose 2.06 million barrels last week, a lower-than-forecast increase.
V: 214.66 (-2.05), GILD: 110.72 (-2.73), FB: 75.86 (-4.91), MET: 52.31 (+0.17), XOM: 94.59 (-0.51), DB: 31.20 (-1.28), FCAU: 10.85 (+1.13), SNY: 45.22 (-2.85)

Early Glance: Biotechnology companies
AP - Wed Oct 29, 9:53AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)

Cramer: Don't Sell U.S. Steel or Gilead Sciences on Earnings
at The Street - Wed Oct 29, 9:53AM CDT
TheStreet's Jim Cramer said U.S. Steel is a great comeback story, while investors shouldn't give up on Gilead Sciences following its earnings report.
GILD: 110.72 (-2.73), X: 40.08 (+1.93)

Gilead Sciences (GILD) Stock Declines After Weak Third-Quarter Results
at The Street - Wed Oct 29, 9:37AM CDT
Shares of Gilead Sciences (GILD) declined in morning trading Wednesday after the biotech company reported third-quarter earnings that came up short of analysts' expectations.
GILD: 110.72 (-2.73)

Stocks Stage Mixed Start; Facebook Drags Down Nasdaq
at Investor's Business Daily - Wed Oct 29, 9:31AM CDT
Stocks opened mixed Wednesday, with the Dow Jones industrial average up 0.3%, the S&P 500 up 0.2% and Facebook dragging the Nasdaq down 0.3%. Volume rose 38% on the Nasdaq and was 3% higher on the NYSE, compared to trade at the same time Tuesday. The...
AMBA: 42.35 (+0.91), GPRO: 67.89 (-1.41), V: 214.66 (-2.05), ORB: 25.27 (-5.10), BIDU: 224.55 (-4.41), GILD: 110.72 (-2.73), MET: 52.31 (+0.17), KRFT: 56.91 (-0.34)

Gilead Sciences (GILD) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Oct 29, 8:30AM CDT
The following Gilead Sciences (GILD) conference call took place on October 28, 2014, 04:30 PM ET. This is a transcript of that earnings call:
GILD: 110.72 (-2.73)

Stock Market Today: Futures Turn Mixed Ahead of Fed Meeting as Facebook Tumbles
at The Street - Wed Oct 29, 8:12AM CDT
U.S. stock futures are mixed as the Federal Reserve concludes a two-day meeting, where the central bank is widely expected to officially end its monthly bond buying program.
V: 214.66 (-2.05), GILD: 110.72 (-2.73), FB: 75.86 (-4.91), MET: 52.31 (+0.17), XOM: 94.59 (-0.51), DB: 31.20 (-1.28), FCAU: 10.85 (+1.13), SNY: 45.22 (-2.85)

Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 186.77 (+4.17), GILD: 110.72 (-2.73), MRK: 56.20 (+0.35), ABBV: 59.98 (-0.95)

Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly
PR Newswire - Wed Oct 29, 7:35AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Edwards Lifesciences Corp. (NYSE: EW) and Eli Lilly and Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7520-100free.
GILD: 110.72 (-2.73), PFE: 29.49 (+0.40), EW: 120.00 (+1.72), LLY: 65.49 (+0.66), ABBV: 59.98 (-0.95)

'Fast Money' Recap: Facebook Expenses Overshadows Great Earnings
at The Street - Wed Oct 29, 4:00AM CDT
The trading panel discussed Facebook and other companies reporting earnings including U.S. Steel and Panera Bread.
HYG: 92.49 (-0.07), EA: 38.91 (+1.43), PNRA: 165.42 (-5.58), FB: 75.86 (-4.91), NNA: 2.96 (+0.11), FCX: 28.99 (-0.04), HIG: 38.87 (+0.07), YHOO: 45.43 (-0.44), GILD: 110.72 (-2.73), CMG: 639.86 (-5.99), NDLS: 21.01 (-0.67), LOCO: 36.71 (+0.29), TWTR: 42.08 (-1.70), X: 40.08 (+1.93), AAPL: 107.34 (+0.60), APC: 91.32 (+0.97), BABA: 98.31 (-1.37)

Hepatitis C: Australia Refuses to Subsidize Costly New Drug; CBCD Reviews a Report
PRWeb - Tue Oct 28, 11:09PM CDT
"Infected with the hepatitis C virus (HCV)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
GILD: 110.72 (-2.73)

Gilead (GILD) Posts Weak Earnings; Stock Falls 4% After-Hours - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Oct 28, 10:58PM CDT
Investors are not loving the latest earnings report from Gilead (GILD) pushing the stock lower by 4 percent after hours.
BIIB: 315.06 (-2.97), GILD: 110.72 (-2.73), ILMN: 188.88 (-1.77)

What to Make of Gilead Sciences Inc.'s Third-Quarter Earnings Miss
Keith Speights, The Motley Fool - Motley Fool - Tue Oct 28, 5:48PM CDT
Gilead Sciences reported its third-quarter financial results after the market closed on Tuesday, and a quick glance at the stock's price would certainly lead you to think those results weren't good, as shares fell more than 3% immediately after the...
GILD: 110.72 (-2.73)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cooper's Heat Pump Campaign Fuels Denver's Community

How Heat Pumps Meet Philanthropy in Denver Alright, let me lay it out for you—a story as much about ingenuity as generosity. Cooper Heating & Cooling, donning their ‘Cooper Green Team’ capes, just wrapped up one heck of a community-driven campaign. They dropped a cool $5,000 into the coffers of We Don't Waste, a Denver nonprofit focused on food recovery. This...

CVRx Faces Legal Storm: Class Action Threat Looms

Cracks in the Foundation: CVRx's Turmoil Let me tell you, it's not every day you see a company drop a bombshell on investors like CVRx did, shaking up the ole portfolio right down to its socks. NASDAQ:CVRX has found itself embroiled in a class action lawsuit courtesy of a knotty mix of legal woes, unplanned revenue slashes, and executive shake-ups. A few short years ago,...

RAI's TrustX Lab Unveils AI Assurance Framework

Pushing the Envelope on AI Control Alright, AI wonks, the Responsible AI Institute just introduced a new sheriff in town. It's called the TrustX Assurance Lab, and it was rolled out during RAISE 2026. We're talking about an independent setup designed to answer whether autonomous AI can stay within its limits. Who's involved? A lot of brainpower from member organizations...

Shukla MD's New Concierge Program Boosts Patient Care

Shifting the Healthcare Paradigm Imagine a healthcare world where doctors actually have the time to listen and engage with you beyond just scribbling notes in haste. That's what's brewing over in Westchester, where Dr. Rachana and Dr. Vaishalee Shukla are putting the old-school patient-doctor relationship front and center with their Hybrid Choice concierge program. Run...

CaliberMRI Revolutionizes Preclinical MRI with New Phantom

CaliberMRI: Pioneers Shaping the Future of MRI Hot off the press, folks—CaliberMRI, known for setting the bar high in MRI standardization, has unleashed a new beast on the scene. Enter Model 340, a preclinical quantitative MRI phantom, ready to knock the socks off high-field systems. They’re talking 4.7T, 7T, and a jaw-dropping 9.4T compatibility here. This isn't just...

Capital Properties Faces Leadership Challenge Amid Health News

Leadership Takes an Unexpected Turn at Capital Properties When the helm of a ship faces turbulence, everyone's eyes turn to the captain. In the case of Capital Properties, Inc., their captain, Chairman, CEO and President Robert H. Eder, has hit a personal snag, diagnosed with cancer but determined to steer steady despite the storm brewing within. A Glance at Capital...

Meijer Team Gives Fuels Midwest Nonprofits: $3M Impact

Power to the Team: Meijer Makes Big Moves On any ordinary day, you'd see folks in Grand Rapids, Michigan, bustling about their routines, but today packs a different vibe. Meijer, the retailer that's been around the block a few times, is handing over a serious chunk of change to the tune of $3 million. This ain't just some half-hearted corporate stunt. Nope, this is the...

Graphy's EU-MDR Milestone: A New Era for Dental 3D Printing

TeraHarz Material Certification: A Step Forward The medical device world has its own Everest, and for Graphy Inc., scaling it means navigating the EU's toughened Medical Device Regulation. They’ve done just that for five of their TeraHarz materials, gearing up to snatch those shiny CE-MDR certificates soon. For anyone keeping tabs on the dental market, that’s a big...

Outdoor Learning: Sparking Preschool Curiosity Weekly

Rekindling Curiosity in Nature’s Classroom With autumn’s crisp air rolling into Greenville, families have a golden opportunity to take learning beyond the traditional classroom. Archway Academy sees the beauty of this season as a sprawling classroom, one that doesn't confine young minds and bodies. For those of us focused more on dollars and sense, the financial...

Budget Airlines' Woes Reveal Travel Insurance Pitfalls

A Turbulent Ride for Travelers Man, it seems like the skies aren't so friendly nowadays, especially if you've got your hard-earned dollars wrapped up in a flight with a budget airline like Spirit or JetBlue. Here's the latest scoop: JetBlue's finances are under the microscope, and if you're planning to fly with them, you better become a travel insurance expert pronto. The...